Avloclav 875mg+125mg (Co-amoxiclav 1000) – High-Dose Adult Antibiotic Tablet

1. About Avloclav 1000 (Amoxicillin 875mg + Clavulanic Acid 125mg)

Avloclav 875+125mg tablets are the high-dose, twice-daily (BD) formulation of Co-amoxiclav, manufactured by ACI Limited, Bangladesh. This formulation provides 1.75g amoxicillin per day (875mg × 2) — equivalent to the same daily dose as Avloclav 625 TDS — with the key advantage of reduced total daily clavulanate exposure (250mg vs 375mg), significantly lowering diarrhoea risk. The BD dosing schedule improves adherence and is preferred in patients who experienced significant GI side effects on TDS formulations.

2. Clinical Advantages of BD vs TDS Co-amoxiclav

The 875+125mg BD formulation was developed to address the tolerability limitations of 625mg TDS. Pharmacokinetic-pharmacodynamic rationale: (1) Same amoxicillin exposure: 875mg × 2/day = 1750mg/day vs 500mg × 3/day = 1500mg/day (actually slightly more amoxicillin per day); (2) Reduced clavulanate: 125mg × 2 = 250mg/day vs 125mg × 3 = 375mg/day — clavulanate is the primary cause of GI side effects; (3) BD dosing adherence: Studies consistently show 20–30% better adherence with BD vs TDS regimens; (4) Equivalent efficacy: Multiple RCTs demonstrate non-inferiority of BD vs TDS co-amoxiclav for all major indications. For patients who cannot tolerate 625mg TDS due to diarrhoea, switching to 875+125mg BD is the evidence-based approach.

3. Indications

• Moderate-to-severe community-acquired pneumonia requiring high amoxicillin exposure
• Moderate-to-severe acute bacterial sinusitis (particularly when DRSP suspected)
• Complicated UTI and pyelonephritis in outpatient setting
• Moderate diabetic foot infection — first-line oral for outpatient-manageable DFI
• Step-down from IV co-amoxiclav in hospital setting
• Skin and soft tissue infections with known or suspected MSSA
• Bite wounds (animal and human)
• Patients intolerant of TDS regimens who require co-amoxiclav

4. Dosage

Adults: One tablet (875+125mg) twice daily (BD) for 5–14 days, taken at start of meals. Do not use in patients with eGFR <30 mL/min — use lower-dose formulations with extended intervals. For eGFR 30–60 mL/min: use with caution, monitor. The higher clavulanate concentration means BD dosing is still preferable to TDS in renal impairment patients to minimise clavulanate accumulation.

5. Contraindications

• Penicillin/amoxicillin/clavulanate hypersensitivity
• Previous amoxicillin-clavulanate-associated liver injury
• Infectious mononucleosis
• eGFR <30 mL/min (use lower-dose formulations)

6. Avloclav 1000 for Moderate Diabetic Foot Infection

Moderate DFI with suspected polymicrobial flora (gram-positive + anaerobes + gram-negatives) is a primary indication for high-dose co-amoxiclav. The 875+125mg BD formulation is preferred over 625mg TDS because: (1) Higher amoxicillin dose ensures adequate tissue penetration in oedematous, poorly vascularised diabetic foot tissue; (2) BD adherence is critical in outpatient DFI management where non-adherence risks treatment failure and limb loss; (3) Reduced diarrhoea (less clavulanate/day) maintains treatment adherence. Use for 7–14 days depending on clinical response. Combination with metronidazole may be needed for deep anaerobic infections. Blood glucose optimisation (target 6–10 mmol/L) is essential — hyperglycaemia impairs neutrophil function and antibiotic efficacy.

7. Side Effects

Common: Diarrhoea (lower incidence than TDS — one of the key advantages), nausea, abdominal discomfort (take with food). Uncommon: Oral/vaginal candidiasis, urticaria. Rare: Cholestatic hepatitis (clavulanate), anaphylaxis, pseudomembranous colitis (C. difficile).

Frequently Asked Questions (FAQ)

Q1: What is the difference between Avloclav 1000 (875+125mg BD) and Avloclav 625 (500+125mg TDS)?

Both contain amoxicillin + clavulanate but differ importantly: Avloclav 1000 (875+125mg BD) — higher per-dose amoxicillin (875mg), lower total daily clavulanate (250mg), twice-daily dosing, better adherence, lower diarrhoea incidence, preferred for patients who cannot tolerate TDS. Avloclav 625 (500+125mg TDS) — lower per-dose amoxicillin (500mg), higher total daily clavulanate (375mg), three-times-daily dosing, historically the standard formulation. Daily amoxicillin: 1000 gives 1750mg/day vs 625 gives 1500mg/day — the 1000 formulation provides modestly higher daily amoxicillin. Clinical impact: both are equivalent for most standard indications; the 1000 BD formulation is preferred when adherence is a concern or when patients had GI intolerance on 625 TDS.

Q2: Can Avloclav 875+125mg be used for bite wound infections?

Yes — co-amoxiclav 875+125mg BD is the standard first-line treatment for infected bite wounds (animal and human) in most guidelines including NICE. Rationale: bite wound infections are polymicrobial, including Pasteurella multocida (cat/dog bites), Capnocytophaga canimorsus, Eikenella corrodens (human bites), streptococci, staphylococci, and oral anaerobes — all within the co-amoxiclav spectrum. Duration: 5–7 days for prophylaxis after high-risk bites (cat bites, deep puncture wounds, hand wounds, immunocompromised host); 7–14 days for established infection. Note: Tetanus prophylaxis and rabies assessment are separate considerations after bite wounds. For patients with penicillin allergy: doxycycline + metronidazole is an alternative.

Q3: Should Avloclav 1000 be used in patients with kidney disease?

The 875+125mg formulation should be avoided in patients with eGFR below 30 mL/min. Both amoxicillin and clavulanate are renally excreted — accumulation in severe renal impairment increases risk of CNS toxicity (high-dose amoxicillin) and GI toxicity. Guidance by eGFR: eGFR >60 mL/min: standard dose (875+125mg BD) is appropriate; eGFR 30–60 mL/min: use with caution, standard BD dose is acceptable but monitor; eGFR 10–30 mL/min: reduce to 500+125mg BD (not TDS, not 875mg dose); eGFR <10 mL/min: 250+125mg BD maximum; haemodialysis: additional dose after each dialysis session. For diabetic nephropathy patients on SGLT2-inhibitors: hold SGLT2-inhibitor during moderate-severe infection (sick day rules) — reduces AKI risk and potential euglycaemic DKA risk.

Q4: How long does it take for Avloclav to work for a skin infection?

For skin and soft tissue infections (cellulitis, wound infection), Avloclav 875+125mg BD typically produces visible clinical improvement within 48–72 hours of starting treatment. Reassessment at 48–72 hours is the clinical standard: (1) If improving (reduced erythema, reduced warmth/swelling, pain decreasing, no fever): continue for the full 7-day course; (2) If not improving: reassess — possible MRSA (co-amoxiclav has no MRSA activity — need clindamycin, TMP-SMX, or doxycycline), deeper infection requiring surgery (necrotising fasciitis), or need for IV antibiotics; (3) If worsening: urgent review — ascending cellulitis, lymphangitis, sepsis require immediate IV antibiotics and possible surgical consultation. Drawing a line around the erythema border with a marker at initiation helps objectively monitor spread. In diabetic patients, healing is slower due to impaired immune response and vascular supply — expect 10–14 days for moderate DFI.